News By Tags

Gain a Deep Insight into the Global Healthcare Cold Chain Logistic Services Market
By : krishna sharma | 03-12-2012 | Health and Fitness | Total Views:26
Driven by a strong demand of biopharmaceuticals, vaccines and clinical trial materials; the global market for healthcare cold chain logistic services is expected to grow exponentially in the coming ye More Details
Biosimilar Insulin Products in the US to Grow at a CAGR of 74 Percent over the Period 2013-2020
By : krishna sharma | 01-25-2012 | Industry | Total Views:68
Lantus is expected to be the most lucrative target for biosimilar manufacturers and account for 71% of the total biosimilar Insulin sales by 2020. More Details
The Penetration of Biosimilars in the US Will Vary Across Different Biological Classes
By : krishna sharma | 01-12-2012 | Health and Fitness | Total Views:38
The volume penetration of biosimilars in the US will strongly depend upon the complexity of the molecule, the patient pool that it caters and the extent of savings it brings to payers and providers More Details
New Report Suggests that Roche is Less Exposed to Biosimilars than Amgen
By : krishna sharma | 11-29-2011 | Medical | Total Views:56
Excluding Mabthera, Roche’s other brands will face biosimilar competition only after 2019. As a result, the company will suffer most of its brand erosion post-2020. More Details
Biosimilars for Blood Disorder Indications in the US Will Reach More Than US$ 2.4 Billion in 2020
By : krishna sharma | 11-17-2011 | Business | Total Views:34
Biosimilar versions of Epogen (Epoetin Alfa) may be launched as early as 2013. This launch is expected to be followed by launches of biosimilar versions of Neupogen (Filgrastim) and Neulasta (Pegfilgr More Details
Biosimilar/Follow-on Monoclonal Antibodies: The Next Big Thing for Generic Manufacturers
By : krishna sharma | 11-02-2011 | Medical | Total Views:34
With the patents of all major monoclonal antibodies set to expire during 2015 - 2020, Biosimilar (or Follow-on) Monoclonal Antibodies are expected to represent the next big thing for generic manufactu More Details
IMARC Group Releases the Most Robust Market Forecast on the US Biosimilar/Follow-on Biologics Market
By : krishna sharma | 10-25-2011 | Business | Total Views:20
With sales worth US$ 57 Million in 2010, biosimilars are still far from their billion dollar sales potential that most analysts believe they will generate. This market, however, unlike small molecule More Details
Orthobiologics to 2016
By : Rajesh Gunnam | 03-02-2011 | Industry | Total Views:78
The Global Orthobiologics Market is Forecast to Reach $9.6 Billion in 2016, Growing at a CAGR of 12% between 2009-2016 More Details
Biotechnology Industry 2010 Yearbook
By : Rajesh Gunnam | 11-23-2010 | Health and Fitness | Total Views:90
In 2009 the Biotechnology Industry was Dominated by the Top 10 Companies More Details
Global Orthobiologics Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016
By : Rajesh Gunnam | 11-23-2010 | Medical | Total Views:102
The Global Orthobiologics Market is Forecast to Reach $9.6 Billion in 2016 after Growing at a CAGR of 12% During 2009-2016 More Details
Page 1 of 2 1 2